Predicting chemotherapeutic response to small-cell lung cancer of platinum compounds by thallium-201 single-photon emission computerized tomography. by Tokuchi, Y. et al.
British Joumal ofCancer(1998) 77(8), 1363-1368
© 1998 Cancer Research Campaign
Predicting chemotherapeutic response to small-cell
lung cancer of platinum compounds by thallium-201
single-photon emission computerized tomography
Y Tokuchil, H Isobe2, H Takekawa1, T Hanada1, T Ishidal, S Ogura1, K Itoh3, M Furudate3, K Saito4 and Y Kawakami'
'First Department of Medicine, School of Medicine, Hokkaido University, Kita 15, Nishi 7, Sapporo, 060, Japan; 2Department of Pulmonary Diseases and Clinical
Research Institute, Sapporo National Hospital, Sapporo, Japan; 3Department of Nuclear Medicine, School of Medicine, Hokkaido University, Kita 15, Nishi 7,
Sapporo, 060, Japan; 4Department of Hygiene and Preventive Medicine, School of Medicine, Hokkaido University, Kita 15, Nishi 7, Sapporo, 060, Japan
Summary Thallium-201 single-photon emission computerized tomography (SPECT) was used to clarify the relationship between 201TI uptake
and the response in chemotherapy to platinum compounds in 21 patients with small-cell lung cancer. 201TI-SPECT scans were obtained twice:
at 15 min (early scan) and 120 min (delayed scan) after an intravenous injection of 111 MBq (3 mCi) ofthallium-201 chloride. We obtained the
uptake ratio from each scan and calculated the retention index:uptake ratio = region of interest uptake / contralateral normal lung uptake;
retention index = (delayed ratio - early ratio)/early ratio. After 201TI scintigraphy, 12 patients received chemotherapy consisting of platinum
compounds and nine were treated with chemoradiation. Among patients receiving only chemotherapy, the retention index correlated with the
responses to chemotherapy. In an in vitro study, ouabain, an inhibitor of the Na,K-ATPase pump, reduced sensitivity to cisplatin and inhibited
intracellular thallium uptake in the small-cell lung cancer cell line. These studies suggest that 201TI-SPECT is a useful indicator of response to
chemotherapy with platinum compounds in small-cell lung cancer, and that Na,K-ATPase is commonly involved in transporting both thallium
and platinum compounds into cancer cells.
Keywords: 201TI-SPECT; chemotherapy; inductively coupled plasma mass spectrometry; cisplatin; Na,K-ATPase
Cisplatin (CDDP) is a useful anti-cancer agent, particularly when
used in the treatment of human ovarian, testicular, bladder and
small-cell lung cancer (Loehrer et al, 1984; Ohmori et al, 1993).
Many studies on cisplatin resistance mechanisms have revealed
that the decline in intracellular accumulation of cisplatin is
important in carcinoma cell lines (Hromas et al, 1987; Kraker
and Moore, 1988; Andrews and Howell, 1990; Mann et al, 1990).
Cisplatin accumulation in these cells is reported to be regulated by
an alteration in their Na,K-ATPase levels (Kawai et al, 1987;
Andrews et al, 1991; Ohmori et al, 1993). Thus, the response
to chemotherapy with cisplatin might depend on alterations of
Na,K-ATPase.
Thallium-201 (201TI) scintigraphy is now used to diagnose
myocardial infarction (Strauss et al, 1975), myocardial ischaemia
(Strauss and Boucher, 1986) and thyroid tumour (Bleichrodt et al,
1987; Charkes et al, 1990). Recently, 207T1 single-photon emission
computerized tomography (SPECT) was reported as being used to
detect lung lesion (Tonami et al, 1989), and it is reportedly supe-
rior to gallium scintigraphy in detecting lung cancer (Itoh et al,
1992; Matsuno et al, 1992). Some studies demonstrated that
TI accumulation in 201T1 scintigraphy is closely related to the
Na,K-ATPase levels in malignant tumours (Britten and Blank,
1968; Muranaka, 1981; Kishida, 1987; Sehweil et al, 1989). And
we reported that the delayed ratio is related to low levels of
Na,K-ATPase activity (Takekawa et al, 1996).
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We hypothesized that the degree of TI uptake to tumour in
201Tl scintigraphy is associated with the response to chemotherapy
with platinum compounds that have uptake mechanisms similar to
TI. To clarify the relationship between TI uptake and the response
to chemotherapy with platinum compounds, we examined patients
with small-cell lung cancers. Furthermore, we studied in vitro the
effect of pretreatment with ouabain, a Na,K-ATPase inhibitor, on
the amount ofintracellular TI uptake and the change in sensitivity
to CDDP to clarify the relationship between intracellular thallium
uptake and sensitivity to cisplatin in the small-cell lung cancer cell
line (Ohmori et al, 1993, 1994).
A new method for the assay ofintracellular T1 accumulation was
used: inductively coupled plasma mass spectrometry (ICP-MS).
ICP-MS is analytical technique with high sensitivity for the deter-
mination oftrace elements in biological samples. The ICP-MS has
several advantages for trace elements determination: simultaneous
multielements determination; ultrasensitive detection; wide
dynamic range (Mauras et al, 1993; Yoshinaga et al, 1993).
MATERIALS AND METHODS
Patients
We studied 25 new patients who had small-cell lung carcinomas:
they were examined by 201TI-SPECT in our hospital from 1991 to
1996. They had received no previous chemotherapy or radiation
therapy. Diagnosis was made by the cytology of the endoscopic
sampling method (catheter biopsy, bronchoalveolar lavage) and/or
histopathology of endoscopic forceps biopsy. We excluded four
patients out of the 25: one patient whose primary nodule was
too small (less than 15 mm in minor axis) for the sensitivity of
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201T1-SPECT in lung cancers (Tonami et al, 1989), one patient who
suddenly died because ofhaemoptysis and two patients who were
given reduced platinum compound doses because of their general
physical condition. Patients were considered to have limited-stage
disease (LD) if detectable cancer was limited to one lung, the
mediastinum and the ipsilateral supraclavicular lymph nodes.
Extensive-stage disease (ED), then, is defined as any stage oflung
cancer more advanced than the limited-stage disease. Each patient
gave informed consent.
201TI-SPECT scanning
Before chemotherapy or chemoradiation therapy, 207T1-SPECT
scans were obtained twice: first at 15 min (early scan) and then at
120 min (delayed scan) after an intravenous injection of 111 MBq
(3 mCi) of thallium-201 chloride. Sehweil et al (1988) reported
that 201T1 uptake occurs rapidly in tumours, with peak values
obtained 10-15 min post-injection in most cases, and there were
no significant changes in tumour-background ratio between the
1 h post-injection image and 4 hpost-injection image. Furthermore,
we have previously reported that 207T1-SPECT scanning at
120 min is associated with the Na,K-ATPase level of the tumour
(Takekawa et al, 1996). Thus, 15 min and 120 min were thought to
be suitable times to take images in 207T1-SPECT. A gamma-camera
(GE-Maxi 400 AT/C) equipped with a parallel-hole collimator was
interfaced with a detection computer (Starcom II). Focusing on the
chest, the detector was rotated in stages of approximately 60 for a
total of3600. Transaxial images were reconstructed with aHanning
pre-filter and a Ramp post-filter. Coronal and sagittal section
images were assembled from transaxial images (Itoh et al, 1992;
Takekawa et al, 1994; Takekawa et al, 1996). Without prior knowl-
edge of the cytological or pathological findings, all of the images
were interpreted for the presence or absence of abnormal accumu-
lations at a conference of nuclear medicine specialists. When the
201T1-SPECT scan showed an abnormal uptake in a lesion, regions
ofinterest (ROTs) were determined and established in both the area
with abnormal radioactivity and the contralateral normal lung on
the coronal sections ofboth the early and delayed scans. The mean
voxel counts for the ROIs were measured and the uptake ratios of
the lesion to the contralateral normal lung were calculated for both
the early and delayed scans. We calculated the retention index
(Tonami et al, 1989; Takekawa et al, 1994) to quantitatively eval-
uate the degree of 20711 retention in the nodule:retention index =
(delayed ratio -early ratio)/early ratio.
Treatment
Protocol was decided by lung cancer treatment committees
according to thepatient's performance status, renal function, respira-
tory function, cardiac condition, liver function and peripheral blood
cell counts. In general, treatment was as powerful as the patients
could bear. After T1 scintigraphy, patients received combination
chemotherapy: CDDP 80 mgm--2onday 1 andetoposide 100 mgm-2
on days 1, 3 and 5 or carboplatin (CBDCA) 300-600mg on day 1
and etoposide 100 mg m-2 on days 1, 3 and 5. Carboplatin dosage
was determined according to Calvert's formula (Calvert et al, 1989).
Thoracic radiation therapy consisting of 50-60 Gy in 20-24
fractions over 5-6 weeks was simultaneously used with
chemotherapy in LD patients who had good respiratory function,
good performance status and no interstitial pneumonitis on chest
radiography or computerized tomography. When the ED patients
had brain metastasis or painful bone metastasis, metastatic sites
were simultaneously treated with radiation therapy. The
chemotherapy group was defined as those treated with
chemotherapy only, and the chemoradiation group was defined as
the patients treated with both chemotherapy and radiation therapy
at any site. Chemotherapy was repeated for at least two courses; in
cases of partial response or complete response, as mentioned
below, chemotherapy was repeated every 4 weeks until the time it
was determined the tumour would not decrease in volume. At that
point, in cases of no change or progressive disease, we chose
palliative therapy forbetter quality oflife ofthe patient.
Response criteria
In chemotherapy, response evaluation was performed using tradi-
tional criteria: a complete response (CR) was defined as the disap-
pearance ofall evidence ofdisease for 4 weeks; a partial response
(PR) was defined as a 50% or greater reduction in the sum of the
product ofthe two greatest perpendicular diameters ofall measur-
able lesions for more than 4 weeks, without the appearance ofnew
lesions or the progression of any lesion; no change (NC) was
defined as a less than 50% decrease or a less than 25% increase in
the sum ofthe product ofthe two greatest perpendicular diameters
of lesions with no new lesions; and progressive disease (PD) was
defined as a 25% or more increase in the size of one or more
lesions, or the appearance of new lesions. A good response was
defined as CR or PR, and the response rate (%) was defined as
good response patients/all patients x 100.
Drugs and chemicals
Thallium was purchased from Wako Chemical (Osaka, Japan);
CDDP and ouabain were purchased from Sigma Chemical (St
Louis, MO, USA); RPMI-1640 was purchased from Nissui
Pharmaceutical (Tokyo, Japan).
Cell line
Human small-cell lung cancer cell line PC-6 was obtained from
the Japanese Cancer Research Resources Bank (Tokyo, Japan).
This cell line was cultivated in tissue culture flasks (Falcon) in
RPMI-1640 medium with 10% fetal bovine serum, 100 units ml-1
penicillin and 100gg ml-' streptomycin.
Thallium accumulation test
PC-6 cells (1 x 106) were preincubated in 10 cm tissue culture
plates (Falcon 3003) overnight. Ouabain (200gM) was added to
the cells and they were incubated for 1 h (subsequently, PC-6/O),
after which the medium was fully vacuumed. An aliquot (10 ml)
of RPMI-1640 containing 10 p.p.m. thallium was added to cells
for 10 min, followed by two washes with phosphate-buffered
saline (PBS). A 1-ml sample of0.9% sodium chloride was added,
and cells were harvestedby scraping and then transferred toplastic
tubes. Next, 1 ml of 100% nitric acid was added to the tubes and
the solutions were taken up into Teflon resolution vessels (Flon
Industry, Tokyo, Japan). The vessels were placed in a vacuum
oven and heated for 2 h. Aftercooling, the samples were diluted to
10 ml with Millipore MiliQ water.
For control PC-6, the same procedures were used, but no
ouabain was added.
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Table 1 Characteristics of chemotherapy patients and responses to therapy
Number Age (years) Sex Retention index Stage Response Regimen
1 61 M 0.39 ED CR CDDP, etoposide
2 64 M 0.14 LD CR CDDP, etoposide
3 72 F 0.28 ED PR CBDCA, etoposide
4 69 M 0.06 ED PR CBDCA, etoposide
5 72 M 0.21 LD PR CDDP, etoposide
6 58 M -0.05 ED NC CDDP, etoposide
7 65 M 0.00 ED NC CDDP, etoposide
8 78 M 0.11 LD NC CDDP, etoposide
9 82 M -0.16 ED NC CBDCA, etoposide
10 63 M 0.12 ED PD CDDP, etoposide
11 79 M 0.00 LD PD CBDCA, etoposide
12 66 M 0.03 ED PD CDDP, etoposide
ED, extensive disease; LD, limited disease.
Instrumentation and samples
The inductively coupled plasma mass spectrometry (ICP-MS)
apparatus used was an SPQ6500 (Seiko Instruments, Shizuoka,
Japan), with a nebulizer and a spray chamber made ofborosilicate
glass. The digested samples were nebulized into ICP-MS without
further dilution. Quantification of all samples was performed
using external standard solutions made up of 1% nitric acid. The
standard solutions used 10, 50 and 100 p.p.b. thallium and, as a
control solution, 0.1% nitric acid. Each experiment was repeated
three times.
Drug sensitivity test
Chemosensitivity of the cells to CDDP was determined using the
XTT assay, as previously reported (Scudiero et al, 1988; Kondo
et al, 1994). After preincubation at 37°C overnight, the 200gM
ouabain was added to PC-6 (now, PC-6/O), incubated for 1 h at
37'C and washed twice with PBS. Various concentrations of the
CDDPwere added to PC-6 andPC-6/0, and all cells were incubated
for 1 hand washed twice with PBS. Units of 1000cells were seeded
into 96-well microplates and incubated at 37°C for 96 h. After
incubation, 50,g of 2,3-bis (2-methoxy-4-nitro-5-sulphophenyl)
[(phenyl-amino) carbonyl]-2H-tetrazolium hydroxide (XTT, Sigma,
St Louis, MO, USA) with 0.38 ,ug of phenazine methosulphate
(PMS, Sigma) were added to each well and incubated at 37°C for
4 h. The plates were agitated on a plate shaker for 5 min, and the
absorbance was measured at 450 nm using an ELISA reader. The
drug concentration producing 50% inhibition of growth (IC50) was
determined from a standard concentration-response curve. Each
experiment was repeated three times.
Statistics
In clinical study, between-group comparisons were carried out
using the Mann-Whitney U-test. Differences were considered
significant when the P-value was less than 0.05.
In an in vitro study, comparisons between means of thallium
accumulation and IC50 on CDDP sensitivity test were performed
using Student's t-test. Differences were considered significant
when the P-value was less than 0.05.
RESULTS
The characteristics of the 12 patients treated with only chemo-
therapy are listed in Table 1, and the characteristics of the nine
patients treated with chemoradiation therapy are listed in Table 2.
The overall response rate was 62%; CR rate was 33% of the 21
patients.
Figure 1 shows that the retention indexes for the PR and the CR
groups were significantly higher than those of the PD and the
NC groups among patients treated only with chemotherapy
(P = 0.012). Except for CBDCA patients, the difference is clear
too (P = 0.025). This demonstrated that the retention index was a
reliable indicator forchemotherapy among patients with small-cell
lung carcinomas. However, if we consider all data in both Tables 1
and 2, the difference between them is not clear (P = 0.075):
combining radiation therapy with chemotherapy might overcome
the relationship between the retention index and the effect of
chemotherapy. Considering only the patients who did not receive
thoracic radiation (numbers 2, 4, 6, 7 in Table 2) in Table 1, the
difference was statistically consistent (P = 0.043).
In contrast, the early ratio and the delayed ratio showed no asso-
ciation with chemotherapeutic response among these patients (data
not shown).
Figure 2 shows the standard curve for thallium determination by
ICP-MS. The correlation coefficient of the regression line was
0.999. ICP-MS is an analytic technique with high sensitivity, and
the standard curve has a wide linear range in measuring Ti
concentration, as previously reported (Yoshinaga, et al, 1993;
Mauras et al, 1993).
Intracellular thallium uptake is demonstrated in PC-6 and PC-
6/0, as ouabain-treated PC-6 cells, in Figure 3. The level ofintra-
cellular thallium in PC-6/O is clearly lower than in PC-6 after
contact with thallium. We obtained the same result with successive
experiments: Ouabain reduced intracellular thallium uptake in the
PC-6 cell line.
Figure 4 shows the result of the cisplatin sensitivity test. PC-
6/0 was pretreated with ouabain and showed less response to
CDDP than did PC-6. The IC50 for PC-6 was 3.1 gm; for PC-6/O,
5.1 gM. There is a significant difference between them (P < 0.05),
demonstrating that ouabaine reduced sensitivity to CDDP in the
PC-6 cell line.
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Table 2 Characterisics of patients receiving chemoradiation therapy and responses to therapy
Number Age (years) Sex Retention index Stage Response Regimen
1 72 M 0.00 LD CR CDDP, etoposide
2 64 M 0.03 ED CR CDDP, etoposide
3 68 F 0.22 LD CR CDDP, etoposide
4 74 F 0.07 ED CR CDDP, etoposide
5 74 M 0.01 LD CR CBDCA, etoposide
6 56 M 0.00 ED PR CDDP, etoposide
7 75 M 0.20 LD PR CBDCA, etoposide
8 60 M 0.08 ED PR CDDP, etoposide
9a 65 M 0.18 ED PD CBDCA, etoposide
LD, limited disease; ED, extensive disease. apatient number 9 was simultaneously given treatment with thoracic radiation because the primary tumour had
painfully invaded the chest wall.
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Figure 1 Retention index and responses to chemotherapy among patients
with small-cell carcinomas. Points and bars are mean and standard
deviations (s.d.) PC-6 PC-6/0
Figure 3 Amount of cellular TI in PC-6 and PC-6/0. 0, PC-6; O, PC-6/0.
Each data point and bar are the mean and s.d. of three experiments
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DISCUSSION
0| Thallium-201 chloride has beendescribed as apositive indicatorfor
lung cancer (Cox et al, 1976; Salvatore et al, 1976; Tonami et al,
0o 1976). SPECT provides a significant improvement, with respect to
theradiopharmaceutical distribution in thebody inthreedimensions
0o and the ability to extract true quantitative values from structures
deep within the body (Matsuno et al, 1992; Yokoi et al, 1994).
0o 207T1-SPECT has been reported to visualize lung cancers as small as
1.5 x 1.0cm (Tonami, et al, 1989), and 1.0 x 1.0 cm (Matsuno et al,
t0 1992). It is possible to diagnose a lung tumour largerthan 15 mm in
diameter as benign ormalignant (Tonami et al, 1989).
0 2 The accumulation patterns of207T1 on early and delayed scans
differ between benign and malignant lung and thyroid tumours TI concentration (p.p.b.) (Ochi et al, 1982; Tonami et al, 1989; El-desouki 1991). In benign
tumours, 201T1 shows either negative or reduced accumulation on
libration curve on measuring TI with ICP-MS the delayed scan. Malignant tumours, on the other hand, clearly
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Figure 4 CDDP sensitivity tests. 0, PC-6; C, PC-6/0. Each data point and
bar are the mean and s.d. of three experiments
show accumulation of 201TI on both the early and the delayed
scans. Retention of201TI on the delayed scan is strongly suggestive
of malignancy. In rats, the 201T1 accumulation revealed in inflam-
matory lesions decreased with time, but 201TI washout from
malignant tumours tended to be delayed (Ando et al, 1987).
In 201TI scintigraphy, the early ratio in a tumour reflects vascu-
larity (Taguchi 1992) and blood pooling (Caluser et al, 1992),
whereas the delayed ratio reflects the cell's ability to increase
TIINa,K-ATP levels (Ando et al, 1988; Caluser et al, 1992;
Takekawa et al, 1996) as well as the viability of tumour cells
(Mountz, et al 1989; Sehweil et al, 1989). The retention index was
defined thus: retention index = (delayed ratio - early ratio)/early
ratio. Defining the early ratio as vascularity and the delayed ratio
as Na,K-ATPase, this formula would mean that Na,K-ATPase
varied with vascularity. Therefore, the retention index would be a
stronger indicator of active transportation by Na,K-ATPase into
cancer cells in the body than would the delayed ratio by itself.
In an in vitro study, influx of thallium into malignant cells is
regulated by its active transportation by Na,K-ATPase (Muranaka,
1981; Kishida, 1987; Sehweil et al, 1989). Since we showed that
the Na,K-ATPase inhibitor ouabain blocks intracellular thallium
uptake in the PC-6 cell line, Na,K-ATPase must play a vital role in
intracellular thallium uptake.
In this study, the retention index of201TI-SPECT was associated
with the response to chemotherapy with platinum compounds in
small-cell lung carcinomas. Therefore, the retention index might
be an indicator of response to chemotherapy with platinum
compounds in small-cell lung carcinomas.
Although chemotherapy with platinum compounds has potency
in small-cell lung cancers, especially in combination with etopo-
side (Seifter and Ihde, 1988), the responses vary from complete
recovery to progression of the disease. Cisplatin accumulation in
these cells is probably regulated by an alteration in their Na,K-
ATPase levels (Kishida, 1987; Andrews et al, 1991; Ohmori et al,
1993). Many cisplatin-resistant cell lines show cross-resistance to
carboplatin (Kraker et al, 1988; Ohmori et al, 1993). Ohmori
reported that PC-14/CDDP, a cisplatin-resistant non-small-cell
lung cancer cell line, showed 3.5-fold resistance to carboplatin,
and that the accumulation ofcisplatin and carboplatin decreased to
23% and 27%. In addition, ouabain inhibited 60% ofCDDP accu-
mulation in PC-14, whereas the same dose of ouabain did not
affect CDDP accumulation in PC-14/CDDP (Ohmori et al, 1993).
Thus, carboplatin may behave similarly to cisplatin on drug-resis-
tantmechanisms. With or withoutcarboplatin groups, there was no
difference in this clinical study in the relationship between 207T1
accumulation and the chemotherapy effect.
Our in vitro study suggested that the sensitivity to CDDP might
be associated with the intracellular uptake of thallium by alter-
ations in Na,K-ATPase in the small-cell lung cancer cell line. In
addition, the accumulation in cancercells ofthallium andplatinum
compounds might be regulated by a common mechanism: active
transportation by Na,K-ATPase. Together, these indicated that the
accumulation shown in the tumour in 201Tl-SPECT correlated with
that ofthe platinum compounds. To our knowledge, this is the first
report demonstrating a significant relationship between the uptake
ratios of 207T1-SPECT and the prediction of chemoresponse to
platinum compounds.
Because we used the standard treatment for small-cell lung
cancer patients in this clinical study, i.e. combination
chemotherapy with platinum compounds andetoposide, we cannot
disregard etoposide effects. Therefore, other studies might be
needed to determine the effects ofetoposide.
Recently rubidium-82 (82Rb) and positron emission tomography
(PET) have been used to diagnose myocardial infarction
(Goldstein et al, 1986). Because 82Rb is taken up into cells by
Na,K-ATPase in the same way as 207T1 - and as PET gives more
accurate images than 207T1 SPECT - a follow-up study using
82Rb and PET might clarify the relationship between uptake and
chemotherapeutic response.
The benefit of 207T1-SPECT is its non-invasiveness: 207T1-
SPECT can give a safe, reliable prediction on a patient's response
to chemotherapy. If we can predict the response, we can avoid
ineffective chemotherapy and unfavourable toxicity, and choose
more suitable drugs for lung cancer patients.
In conclusion, 207T1-SPECT could be a useful indicator of
response to chemotherapy with platinum compounds in lung
cancers.
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